SG11201908784TA - Improved antigen binding receptor formats - Google Patents

Improved antigen binding receptor formats

Info

Publication number
SG11201908784TA
SG11201908784TA SG11201908784TA SG11201908784TA SG 11201908784T A SG11201908784T A SG 11201908784TA SG 11201908784T A SG11201908784T A SG 11201908784TA SG 11201908784T A SG11201908784T A SG 11201908784TA
Authority
SG
Singapore
Prior art keywords
antigen binding
international
atm
roche
csd
Prior art date
Application number
Inventor
Christian Klein
Ekkehard Moessner
Diana Darowski
Kay-Gunnar Stubenrauch
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11201908784TA publication Critical patent/SG11201908784TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464424—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) WIPO I PCT (51) International Patent Classification: A61K 39/395 (2006.01) C07K 14/735 (2006.01) (71) Applicant all designated States except US): F. HOFF- MANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse A61K 35/17 (2015.01) C07K 16/28 (2006.01) 124, 4070 Basel (CH). C07K 14/725 (2006.01) C07K 16/30 (2006.01) C07K 14/705 (2006.01) A61K 39/00 (2006.01) (71) Applicant (for US only): HOFFMANN-LA ROCHE (21) International Application Number: INC. [US/US]; Overlook at Great Notch, 150 Clove Road, 8th Floor, Suite 8 - Legal Department, Little Falls, New Jer- PCT/EP2018/057567 sey 07424 (US). omit VIII °nolo olo VIII lII 1111111 ow (10) International Publication Number WO 2018/177967 Al (22) International Filing Date: 26 March 2018 (26.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17163090.8 27 March 2017 (27.03.2017) EP 17171775.4 18 May 2017 (18.05.2017) EP (72) Inventors: KLEIN, Christian; c/o Roche Glycart AG, Wagistrasse 18, 8952 Schlieren (CH). MOESSNER, Ekke- hard; c/o Roche Glycart AG, Wagistrasse 18, 8952 Sch- lieren (CH). DAROWSKI, Diana; c/o Roche Glycart AG, Wagistrasse 18, 8952 Schlieren (CH). STUBENRAUCH, Kay-Gunnar; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). (74) Agent: BRODBECK, Michel; Grenzacherstrasse 124, 4070 Basel (CH). (54) Title: IMPROVED ANTIGEN BINDING RECEPTOR FORMATS Figure 1A Figure 1B Figure 1C linker VL CL linker VH VH CH CH VH CH ATM CSD SSD VL CL VL CL ATM CSD SSD ATM CSD SSD 1-1 N 1-1 00 1-1 O Fab Format Fab Format VL-CL-ATM scFab Format ATM = anchoring transmembrane domain; CSD = co-stimulatory signaling domain ; SSD = stimulatory signaling domain (57) : The present disclosure generally relates to antigen binding receptors in new formats capable of specific binding to a tumor associated antigen. More precisely, the present invention relates to an antigen binding receptor which efficiently and specifically binds to/interacts with an antigen on the surface of a tumor cell, and to a T cell transfected/transduced with the antigen binding receptor. Furthermore, the invention relates to nucleic acid molecules and vectors encoding antigen binding receptors of the present invention. The invention also provides the production and use of T cells in a method for the treatment of particular diseases as well as pharmaceutical compositions/medicaments comprising antigen binding receptors and/or T cells of the present invention. [Continued on next page] WO 2018/177967 Al IMEDIMOMMIONE1013010BEHOHNEMOVOIMIE (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))
SG11201908784T 2017-03-27 2018-03-26 Improved antigen binding receptor formats SG11201908784TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17163090 2017-03-27
EP17171775 2017-05-18
PCT/EP2018/057567 WO2018177967A1 (en) 2017-03-27 2018-03-26 Improved antigen binding receptor formats

Publications (1)

Publication Number Publication Date
SG11201908784TA true SG11201908784TA (en) 2019-10-30

Family

ID=61800534

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908784T SG11201908784TA (en) 2017-03-27 2018-03-26 Improved antigen binding receptor formats

Country Status (19)

Country Link
US (1) US20200093861A1 (en)
EP (1) EP3600408A1 (en)
JP (1) JP2020511979A (en)
KR (1) KR20190133017A (en)
CN (1) CN110461360A (en)
AU (1) AU2018241625A1 (en)
BR (1) BR112019017629A2 (en)
CA (1) CA3054104A1 (en)
CL (1) CL2019002686A1 (en)
CR (1) CR20190431A (en)
IL (1) IL268824A (en)
MA (1) MA49355A (en)
MX (1) MX2019011656A (en)
PE (1) PE20191703A1 (en)
RU (1) RU2019133199A (en)
SG (1) SG11201908784TA (en)
TW (1) TW201900672A (en)
WO (1) WO2018177967A1 (en)
ZA (1) ZA201905519B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR106188A1 (en) 2015-10-01 2017-12-20 Hoffmann La Roche ANTI-CD19 HUMANIZED HUMAN ANTIBODIES AND METHODS OF USE
JP7022123B2 (en) * 2016-09-30 2022-02-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Bispecific antibody against CD3
CN108395482B (en) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 Construction of targeting CD20 antigen chimeric antigen receptor and activity identification of engineered T cell thereof
RU2019133202A (en) 2017-03-27 2021-04-28 Ф. Хоффманн-Ля Рош Аг IMPROVED ANTIGEN BINDING RECEPTORS
US20200223925A1 (en) * 2018-12-21 2020-07-16 Hoffmann-La Roche Inc. Tumor-targeted superagonistic cd28 antigen binding molecules
MA54513A (en) * 2018-12-21 2022-03-30 Hoffmann La Roche CD28 ANTIGEN BINDING MOLECULES TUMOR TARGETING AGONISTS
CN110317277A (en) * 2019-07-10 2019-10-11 杭州普科亭生物医药有限公司 Chimeric antigen receptor and its application
TW202142570A (en) * 2020-04-30 2021-11-16 大陸商正大天晴藥業集團股份有限公司 Antigen binding constructs targeting her2 and uses thereof
WO2022040454A1 (en) 2020-08-20 2022-02-24 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers
CA3188867A1 (en) * 2020-08-20 2022-02-24 Xueyin Wang Compositions and methods for treating ceacam positive cancers
CN114990129B (en) * 2022-05-11 2023-02-03 北京贝来生物科技有限公司 Preparation and application of mesenchymal stem cells expressing alpha PDL1: fc fusion protein

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2919890B2 (en) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル Single domain ligand, receptor consisting of the ligand, method for producing the same, and use of the ligand and the receptor
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
GB9304200D0 (en) 1993-03-02 1993-04-21 Sandoz Ltd Improvements in or relating to organic compounds
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
ATE295420T1 (en) 1992-02-06 2005-05-15 Chiron Corp MARKER FOR CANCER AND BIOSYNTHETIC BINDING PROTEIN FOR IT
US5910488A (en) 1993-06-07 1999-06-08 Vical Incorporated Plasmids suitable for gene therapy
JPH11509088A (en) 1995-06-23 1999-08-17 プレジデント アンド フェローズ オブ ハーバード カレッジ Transcriptional regulation of the gene encoding vascular endothelial growth factor receptor
WO2001044463A1 (en) 1999-12-15 2001-06-21 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
AU2003239966B9 (en) 2002-06-03 2010-08-26 Genentech, Inc. Synthetic antibody phage libraries
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
US7722867B2 (en) 2005-02-07 2010-05-25 Glycart Biotechnology Ag Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
WO2007056441A2 (en) 2005-11-07 2007-05-18 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
AU2007249408A1 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
CN100592373C (en) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 Liquid crystal panel drive device and its drive method
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20110280894A1 (en) 2008-07-31 2011-11-17 Angela Krackhardt Her2/neu specific t cell receptors
KR20140004174A (en) * 2011-01-18 2014-01-10 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Compositions and methods for treating cancer
MX336740B (en) 2011-03-29 2016-01-29 Roche Glycart Ag Antibody fc variants.
PE20141521A1 (en) 2011-08-23 2014-10-25 Roche Glycart Ag T-CELL ACTIVATING ANTIGEN-BINDING BI-SPECIFIC MOLECULES
CN104379601B (en) * 2012-02-03 2021-04-09 霍夫曼-拉罗奇有限公司 Bispecific antibody molecules and antigen-transfected T-cells and their use in medicine
WO2014055771A1 (en) * 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
EP3811970A1 (en) * 2014-03-15 2021-04-28 Novartis AG Regulatable chimeric antigen receptor
UA117289C2 (en) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Multispecific antibodies
WO2015179833A1 (en) * 2014-05-23 2015-11-26 The Trustees Of The University Of Pennsylvania Compositions and methods for treating antibody resistance
SG11201610170SA (en) * 2014-06-06 2017-01-27 Bluebird Bio Inc Improved t cell compositions
PE20211533A1 (en) 2014-08-04 2021-08-16 Hoffmann La Roche BISPECIFIC MOLECULES OF UNON TO ANTIGEN ACTIVATING T-CELLS
EP3191507A1 (en) * 2014-09-09 2017-07-19 Unum Therapeutics Chimeric receptors and uses thereof in immune therapy
WO2016126608A1 (en) * 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
US9574014B2 (en) 2015-05-15 2017-02-21 City Of Hope Chimeric antigen receptor compositions
EP3344262A4 (en) * 2015-09-01 2019-03-20 Innate Tumor Immunity, Inc. Immune cells having increased immunity or resistance to an immunosuppressive cytokine and use of the same
EP3356418A4 (en) * 2015-10-01 2019-07-03 The Centre for Drug Research and Development Anti-podocalyxin antibodies and methods of using the same
EP3529279A4 (en) * 2016-10-19 2020-04-29 The Governing Council of the University of Toronto Cd133-binding agents and uses thereof
JOP20180027A1 (en) * 2017-03-28 2019-01-30 Cell Design Labs Inc Chimeric polypeptides and methods of altering the membrane localization of the same

Also Published As

Publication number Publication date
JP2020511979A (en) 2020-04-23
KR20190133017A (en) 2019-11-29
CA3054104A1 (en) 2018-10-04
RU2019133199A (en) 2021-04-28
MX2019011656A (en) 2019-12-02
ZA201905519B (en) 2021-06-30
TW201900672A (en) 2019-01-01
AU2018241625A1 (en) 2019-09-05
WO2018177967A1 (en) 2018-10-04
PE20191703A1 (en) 2019-11-27
CL2019002686A1 (en) 2020-02-14
CN110461360A (en) 2019-11-15
US20200093861A1 (en) 2020-03-26
MA49355A (en) 2020-02-05
BR112019017629A2 (en) 2020-04-07
EP3600408A1 (en) 2020-02-05
CR20190431A (en) 2019-11-01
IL268824A (en) 2019-10-31
RU2019133199A3 (en) 2021-07-09

Similar Documents

Publication Publication Date Title
SG11201908784TA (en) Improved antigen binding receptor formats
SG11201908796XA (en) Improved antigen binding receptors
SG11201908787WA (en) Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
SG11201909154SA (en) Bispecific antibodies specifically binding to pd1 and lag3
SG11201810076WA (en) Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
SG11201900885VA (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
SG11201810697QA (en) Chimeric antigen receptor and car-t cells that bind bcma
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201903825SA (en) Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
SG11201900955VA (en) T cell receptors and immune therapy using the same
SG11201804398XA (en) Method for producing rna molecule compositions
SG11201810777WA (en) Purification of multispecific antibodies
SG11201909646TA (en) Trem2 antigen binding proteins and uses thereof
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201900677SA (en) Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
SG11201804086VA (en) Methods and compositions for nucleic acid analysis
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201804694SA (en) Dual controls for therapeutic cell activation or elimination
SG11201804178YA (en) Pd1 and/or lag3 binders
SG11201807489PA (en) Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
SG11201805449PA (en) Methods of making chimeric antigen receptor -expressing cells
SG11201407669QA (en) Methods for improving safety of blood-brain barrier transport
SG11201908650PA (en) Optimized antibody compositions for treatment of ocular disorders
SG11201906319XA (en) Compositions and methods for the depletion of cd137+ cells
SG11201908326YA (en) Methods of treating neurodegenerative diseases